Clinical Trials on Refractory Myelodysplastic Syndrome in France

Total 3638 results

Groupe Francophone des Myelodysplasies
Roche Pharma AG

Completed

Erlotinib in Higher Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

France
Assistance Publique Hopitaux De Marseille

Unknown

Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine

Myelodysplastic Syndromes | Myeloid Leukemia

France
Bioniche Pharma USA LLC

Completed

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

Myelodysplastic Syndrome

United States, France
Groupe Francophone des Myelodysplasies

Completed

Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200

Myelodysplastic Syndromes

France
Institut Paoli-Calmettes

Recruiting

Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015 (HEMATO-BIO)

Myelodysplastic Syndromes | Myeloproliferative Disorders | Acute Leukemia

France
Groupe Francophone des Myelodysplasies
Merck Sharp & Dohme LLC

Completed

Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia (GFMVOR2007)

Myelodysplastic Syndromes

France
Centre Henri Becquerel

Unknown

Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients (AZABAC)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies

Completed

CPX-351 in Higher Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies

Completed

Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

France
Groupe Francophone des Myelodysplasies

Unknown

Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

France
Hospices Civils de Lyon

Unknown

Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (GREFFE)

Myelodysplastic Syndromes | Myeloid Leukemia

France
Hospices Civils de Lyon

Not yet recruiting

Role of BMP Pathway in MDS Progression (BMP-MDS)

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

France
Institut Paoli-Calmettes

Recruiting

COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (COHABILIT)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

France
Nantes University Hospital

Completed

VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome (VIDAZA-DLI)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

France
GCP-Service International West GmbH
Saint-Louis Hospital, Paris, France; Groupe Francophone des Myelodysplasies; Australasian... and other collaborators

Active, not recruiting

Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (IMpress)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Germany, France, Australia
GWT-TUD GmbH

Terminated

Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY (SAMBA)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

France, Germany
Groupe Francophone des Myelodysplasies
Roche Pharma AG; Celgene Corporation

Completed

Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

Myelodysplastic Syndromes

France
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukaemia (AML)

France, Australia
Groupe Francophone des Myelodysplasies
Merck Sharp & Dohme LLC

Terminated

Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure (GFM-AZA-VOR)

Myelodysplastic Syndrome

France
European Organisation for Research and Treatment...

Completed

Infliximab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

France, Belgium, Netherlands, Czech Republic, Italy, Germany
Onconova Therapeutics, Inc.

Completed

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Myelodysplastic Syndromes

United States, France, Germany
CTI BioPharma
National Cancer Institute (NCI)

Terminated

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Boehringer Ingelheim

Terminated

Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

France, Germany
Groupe Francophone des Myelodysplasies
Aprea Therapeutics

Unknown

Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

Chronic Myelomonocytic Leukemia | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Gene Mutations | Myelodysplastic Syndrome With Gene Mutation

France
Centre Hospitalier Universitaire de Nice

Unknown

Characterization of the Mechanisms of Resistance to Azacitidine

Myelodysplastic Syndromes or Acute Myeloid Leukemia With Multilineage Dysplasia

France, Monaco
Institut Paoli-Calmettes

Unknown

Evaluation of 3 Different Doses of IV Busulfan (AAA)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

France
Fundación General de la Universidad de Salamanca
Celgene Corporation

Completed

Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (SINTRA-REV)

Myelodysplastic Syndrome

Germany, Spain, France
Groupe Francophone des Myelodysplasies

Unknown

SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies

Completed

Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS) (EPO-QoL)

Myelodysplastic Syndromes

France
MedImmune LLC

Completed

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States, United Kingdom, France, Germany
Groupe Francophone des Myelodysplasies
Celgene

Recruiting

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Myelodysplastic Syndromes | MDS

France
Groupe Francophone des Myelodysplasies
Celgene

Completed

Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q (GFM-AZA-REV-09)

Myelodysplastic Syndromes

France
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukaemia (AML)

United States, Australia, France, Spain
University Hospital, Toulouse
National Cancer Institute, France

Completed

PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes. (PREDICTOR)

Myelodysplastic Syndromes

France, Monaco
AbbVie
Genentech, Inc.

Active, not recruiting

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona)

Myelodysplastic Syndrome (MDS)

United States, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Puerto Rico, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, Hungary
Groupe Francophone des Myelodysplasies
Novartis

Completed

A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients (LDE255)

MDS

France
Celgene

Completed

An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

Italy, United Kingdom, Germany, Australia, Bulgaria, France, Greece, Hungary, Netherlands, Poland, Spain
European Organisation for Research and Treatment...

Withdrawn

Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome

Myelodysplastic Syndromes

France, Netherlands, Norway, Belgium, Switzerland, Austria, United Kingdom, Germany, Denmark
Institut Curie
National Cancer Institute, France; Fondation ARC

Terminated

PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)

Acute Myeloid Leukemia, in Relapse | Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome | de Novo Acute Myeloid Leukemia at Diagnostic

France
Janssen-Cilag International NV

Completed

An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

France, Germany, Bulgaria, Greece, Russian Federation
Vion Pharmaceuticals

Completed

VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States, France, United Kingdom
European Organisation for Research and Treatment...

Completed

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

France, Belgium, Portugal
Novartis Pharmaceuticals

Terminated

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Thrombocytopaenia

United States, Belgium, Australia, Canada, Hong Kong, Austria, Brazil, Czechia, Israel, Russian Federation, Spain, Sweden, Thailand, Denmark, France, Germany, Ireland, Italy, Korea, Republic of, Peru, Switzerland, Taiwan, Turkey, Hungary and more
Gesellschaft fur Medizinische Innovation - Hamatologie...
Amgen

Completed

Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia (EUROPE)

Myelodysplastic Syndromes

France, Germany
Assistance Publique - Hôpitaux de Paris

Recruiting

The Patient Cohort of the National Center for Precision Medicine in Leukemia (eTHEMA)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | High-risk Myelodysplastic Syndrome | Myeloproliferative Neoplasm, Unclassifiable | Secondary Myelofibrosis in Myeloproliferative Disease

France
Associazione Qol-one

Terminated

Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q

Myelodysplastic Syndromes

France, Italy, Greece
Assistance Publique - Hôpitaux de Paris

Completed

5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS

Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukaemia (AML)

France
Groupe Francophone des Myelodysplasies

Recruiting

A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS (EPO-PRETAR)

Myelodysplastic Syndromes

France
University Hospital, Caen

Completed

Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)

Cancer

France
Novartis Pharmaceuticals

Active, not recruiting

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). (STIMULUS-MDS1)

Myelodysplastic Syndromes

Czechia, Hungary, Japan, Taiwan, United States, Belgium, Italy, United Kingdom, Korea, Republic of, Hong Kong, Austria, Germany, Turkey, Spain, Greece, France, Canada

Clinical Trials on Refractory Myelodysplastic Syndrome in France

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations